VTv Therapeutics, Cantex Ink Licensing Agreement For Azeliragon To Treat Cancer - Quick Facts

(RTTNews) - Biopharmaceutical company vTv Therapeutics Inc. (VTVT) and Cantex Pharmaceuticals, Inc. announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel orally active, small molecule, antagonist of RAGE (the receptor for advanced glycation endproducts).

Azeliragon is a phase 2-ready oral medication administered once daily, which has demonstrated a good safety profile in several Alzheimer's disease trials

Cantex said it intends to move rapidly to prepare for clinical trials to assess the potential of azeliragon for the treatment of a number of complications associated with cancer.

Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon and the companies will allocate downstream profits under a tiered arrangement.